Mitos da morfina

Autores

  • Maria Fragoso Assistente Graduada de Medicina Interna do Departamento de Oncologia Médica Instituto Português de Oncologia, Porto

Palavras-chave:

mitos da morfina, dor crónica, subtratamento

Resumo

O subtratamento da dor crónica continua a assumir uma dimensão importante, colocando-a
como um problema de saúde pública. As razões apontadas são diversas. Há no, entanto, uma
situação que envolve quer os profissionais de saúde quer os doentes, designada pelos mitos da
morfina, e que poderá justificar alguns dos casos de subtratamento. A partir das questões mais
frequentemente levantadas quer pelos profissionais, quer pelos doentes e familiares, o autor
apresenta uma revisão do tema.

Downloads

Não há dados estatísticos.

Referências

Melzack R. The tragedy of needless pain: a call for social action. Proceedings of the 5th World Congress on Pain 1988.

Banos JE, Bosch F. Opioidphobia and cancer pain. Lancet 1993; 341: 1474.

Melzack R. The tragedy of needless pain. Sci Amer 1990:262: 27-33.

Grossman AS, Sheidler VR. Skills of medial students and house officers in prescribing narcotic medications. J Med Education 1985; 60: 552-557.

Ferrell BR, Eberts MT, McCaffery M, Grant M. Clinical decision making and pain.Cancer Nursing1991; 14 (6): 289-297.

Sheidler VR, McGuire DB, Grossman AS, Gilbert MR. Analgesic decision-making skills of nurses. Oncology Nursing Forum 1992; 19: 1531-1534.

World Health Organization. Cancer pain relief and palliative care: report of a WHO Expert Committee, 3rd ed. Geneva 1996.

Shapiro RS. Legal bases for the control of analgesic drugs. J Pain Symptom Management 1994; 9(3): 153-159.

Jacox A, Carr DB, Payne R, Berde CR, Breitbart W, Cain JM, Chapman CR et al. Management of cancer pain: Clinical practice Guidelines, 1994; nº 9. Agency for Health Care Policy and Research Publication, Rockville.

Porter J, Jick H. Addiction rare in patients treated with narcotics. N Eng J Med 1980; 302: 123 (letter).

Weissman DE, Haddox JD. Opioid pseudo-addiction - na iatrogeic syndrome. Pain 1989; 36(3): 363-366.

Ellison NM. Opioid analgesics for cancer pain: Toxicities and their treatment. RB Patt Ed. Cancer pain pg 185-194. Philadelphia, Lippincott.

Hill CS. Oral opiod analgesics RB Patt Ed. Cancer pain pg 129-142, Philadelphia Lippinccott.

Marks EM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med 1973; 78: 173-181.

Morgan JP, Pleet DL. Opioiphobia in the US: the undertreatment of severe pain. In Morgan JP, Kagan DV eds. Society and medicine: conflicting signals for prescribers and patients. Lexington MA, Lexington Press 1983 :313-326.

Morgan AE, Lindley CM, Berry JL. Assessment of pain and patterns of analgesic use in hospice patients. Am J of Hospice and Palliative care 1994; 11 (1): 13-19, 22-25.

International agency for the study of pain (IASP) Sub-committee on taxonomy. Pin terms: a list with definitions and notes on usage. Pain 1979; 6(2): 249.

Hanks GW, Twycross RG. Painthe physiological antagonist of opioid. Lancet 1984;1: 1477-1478.

Portenoy RK, Khan E, Layman M, Lapin J, Malkin MG, Foley KM, et al. Chronic morphine therapy for cancer pain: plasma and cerebro-spinal fluid morphine and morphine-6-glucoronide concentrations. Neurology 1991; 41: 1457-1461.

Jaffe JH, Martin WR. Opioids analgesics and antagonist in Goodman's and Gilman's The pharmacological basis of therapeutics (ed8) New York, NY Pergamon 1990: 482-521

Ficheiros Adicionais

Publicado

31-12-2002

Como Citar

1.
Fragoso M. Mitos da morfina. RPMI [Internet]. 31 de Dezembro de 2002 [citado 16 de Novembro de 2024];9(4). Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/1873

Edição

Secção

Artigos de Revisão